In agreement with the mentioned observations, colon adenocarcinoma cells, which were able to survive (or still struggling for survival) the therapeutic impact, exhibited a decreased proliferation activity, since the proliferation marker Ki67 was considerably lower in tumors treated with the combinatorial treatment than those treated with the either therapies alone. This evidence concerns the gene MKI67 and colon adenocarcinoma.